- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Episode 21: Southeast Biotech
Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline, talks with Christen Harm and Michelle Maskaly, about the biopharma landscape in the southeastern part of the United States, as part of Pharm Exec’s ongoing series that looks at growing biotech innovation hubs across the country. Bailey gives unmatched insights about the efforts North Carolina has put into growing, attracting, and retaining life science startups, specifically in the Raleigh-Durham area, as well as addresses challenges such as access to venture capital.
Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline, talks with Christen Harm and Michelle Maskaly, about the biopharma landscape in the southeastern part of the United States, as part of Pharm Exec’s ongoing series that looks at growing biotech innovation hubs across the country. Bailey gives unmatched insights about the efforts North Carolina has put into growing, attracting, and retaining life science startups, specifically in the Raleigh-Durham area, as well as addresses challenges such as access to venture capital.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
